leucemia mieloide acuta - · pdf filea.m. carella u.o.c. ematologia irccs aou san martino...
TRANSCRIPT
![Page 1: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/1.jpg)
A.M. Carella U.O.C. Ematologia
IRCCS AOU San Martino – IST, Genova
LEUCEMIA MIELOIDE ACUTA
![Page 2: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/2.jpg)
Impact of mutational analysis in AML
C. Thiede
Optimal acute myeloid leukemia therapy in
2012
H. Dombret
![Page 3: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/3.jpg)
• Acquired mutations and epigenetic
alterations accumulate in progressive way.
• Subclones of cells acquire new properties,
giving cells advantages such as the ability
to resist chemotherapy.
![Page 4: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/4.jpg)
ü MDS clones contain hundreds of
acquired mutations.
ü Leukemias arose from at least one
subclone that had gained new mutations.
ü Sequential development of leukemia.
Walter et al. NEJM 2012; 366:1979
![Page 5: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/5.jpg)
Do they have prognostic value?
Poor Survival:
FLT3+ or MLL and in those with point mutations
of ASXL1 or PHF6.
Favorable Survival:
CEBPA or IDH2 mutations; NPM1 mutations
with concurrent IDH1 or IDH2 mutations.
![Page 6: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/6.jpg)
![Page 7: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/7.jpg)
In a recent comprehensive analysis of
mutations in a cohort of almost 400 pts with
AML treated in the ECOG, reported for the first
time a simultaneous mutational analysis of 18
genes, covering most abnormalities currently
discussed as relevant for AML prognosis.
(Patel et al., NEJM 2012)
![Page 8: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/8.jpg)
![Page 9: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/9.jpg)
![Page 10: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/10.jpg)
![Page 11: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/11.jpg)
![Page 12: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/12.jpg)
![Page 13: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/13.jpg)
![Page 14: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/14.jpg)
![Page 15: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/15.jpg)
ü These data indicate:
a. more detailed genetic analysis may lead to improved risk stratification and identification of patients who can benefit from more intensive induction chemotherapy.
b. the challenge is to provide genetic information in a timely and affordable way and show that this information could prospectively influence treatment decisions.
![Page 16: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/16.jpg)
![Page 17: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/17.jpg)
AML Therapy in 2012 Younger AML
![Page 18: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/18.jpg)
ELN Guidelines 2010 - Induction 18-60 years
ü Standard - 7 + 3
- AraC 100-200 + Dauno 60+, Ida 10-12, Mtx 10-12
- HiDAC too toxic - Phase 3 studies: SWOG 2 g x12, ALSG 3 g x 8 - Phase 2 studies: ECOG 3 g x 6, SWOG 7+3 fw by 2 g x 6 (7+3+3)
ü Promising options
- CSF priming - G-CSF: HOVON-SAKK study - GM-CSF: ALFA study
- Gemtuzumab ozogamicin (GO) - British AML15 study
![Page 19: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/19.jpg)
![Page 20: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/20.jpg)
![Page 21: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/21.jpg)
![Page 22: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/22.jpg)
![Page 23: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/23.jpg)
![Page 24: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/24.jpg)
![Page 25: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/25.jpg)
![Page 26: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/26.jpg)
![Page 27: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/27.jpg)
![Page 28: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/28.jpg)
![Page 29: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/29.jpg)
![Page 30: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/30.jpg)
![Page 31: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/31.jpg)
![Page 32: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/32.jpg)
Inhibition of constitutively activated FLT3,
lestaurtinib in relapsed AML and sorafenib
in newly diagnosed older AML, have failed
to demonstrated significant benefit when
combined to intensive chemotherapy.
Lestaurtinib / Sorafenib
![Page 33: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/33.jpg)
• Phase III randomized study of midostaurin restricted to FLT3 mutated pts younger than 60 yrs is ongoing.
• Phase II study of quizartinib or AC220, the most selective FLT3 inhibitor available, in relapsed AML have confirmed that clonal responses could be observed with monotherapy.
Midostaurin /Quizartinib
![Page 34: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/34.jpg)
• KIT mutation, associated with unfavorable prognosis in CBF-AML, may be targeted with dasatinib.
• A frontline study of dasatinib combined to intensive chemotherapy is ongoing by the AMLSG.
• No responses were observed with dasatinib alone in the French DASA-CBF study.
Dasatinib
![Page 35: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/35.jpg)
![Page 36: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/36.jpg)
![Page 37: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/37.jpg)
Plerixafor, a CXCR4 antagonist blocking the
CXCR4/SDF-1 interaction has been
developed as an agent capable to mobilize
hematopoietic progenitors from the
hematopoietic niche to the peripheral blood.
![Page 38: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/38.jpg)
Evaluating its safety and potential when used
alone or combined with G-CSF as a chemo-
sensitizing agent in AML pts are ongoing.
![Page 39: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/39.jpg)
ALLOGRAFTING
![Page 40: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/40.jpg)
![Page 41: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/41.jpg)
ü Intent to treat donor versus no-donor comparisons is not well suited to evaluate the real effect of HSCT in very high-risk pts.
ü Transplant versus no-transplant comparison should be preferred (as a significant proportion of these pts will never be transplanted in 1st CR despite an identified donor).
![Page 42: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/42.jpg)
![Page 43: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/43.jpg)
ü The value of allogeneic HSCT needs to be reassessed based on:
- the identification of AML genetic heterogeneity. - the availability of different transplant sources and donor types. - The use of reduced-intensity conditioning (RIC).
It is important to consider TRM that may vary between less than 15% and up to 50%. It is essential to assess whether the benefit of the reduced relapse rate outweighs TRM or will be offset by a high TRM.
![Page 44: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/44.jpg)
![Page 45: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/45.jpg)
![Page 46: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/46.jpg)
![Page 47: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/47.jpg)
![Page 48: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/48.jpg)
![Page 49: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/49.jpg)
![Page 50: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/50.jpg)
AML Therapy in 2012 Older AML
![Page 51: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/51.jpg)
![Page 52: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/52.jpg)
• Older age per se, however, should not be a reason to withhold intensive therapy.
• Remission induction chemotherapy provides better quality of life and longer survival than supportive care only.
• Intensive chemotherapy should thus remain the standard in pts capable to tolerate it.
• The 3+7 remains the most frequently used chemotherapy induction regimen.
Standard therapy in older AML pts
![Page 53: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/53.jpg)
![Page 54: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/54.jpg)
![Page 55: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/55.jpg)
![Page 56: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/56.jpg)
![Page 57: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/57.jpg)
Azacitidine and Decitabine:
significant benefit in HR-MDS (and pts
with 20-30% marrow blasts), compared
with conventional care including LDAC.
Hypomethylating Agents
![Page 58: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/58.jpg)
![Page 59: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/59.jpg)
Azacitidine has also shown interesting
results in retrospective AML studies.
![Page 60: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/60.jpg)
Azaci&dine followed by lenalidomide in pa&ents with higher-‐risk MDS or AML; ongoing AZALE study: results
• Median 2 cycles (range 1–6) administered within all dose cohorts
• To date, 20 pa=ents enrolled: – cohort 1 and 2: 4 pa=ents each – cohort 3 and 4: 6 pa=ents each
Platzbecker U, et al. Poster presentation at ASH 2011. Abstract 3799
Patients
Safety • MTD of lenalidomide: 20mg • Therapy-induced grade 3/4 neutropenia or
thrombocytopenia, n (%): 12 (60) • DLTs, n:
• infectious complications: 2 • thrombosis: 1 • incomplete haematological recovery: 1
Response (n=19)
CR PR 0
2
Pat
ient
s, n
Overall = 7 (37%)
3 4
CR CRi HI 0
1
2
3
Pat
ient
s, n
Overall = 6 (32%)
PR
Cytogenetic response (n=19)
4
Sequential azacitidine and lenalidomide is feasible and appears effective in patients with higher-risk MDS/AML and del(5q)
• ORR in previously untreated patients: 5/9 (56%) • Response in patients with p53 mutations: 5/7 (71%)
• 13 (68%) patients had SD
![Page 61: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/61.jpg)
Ulz Krug et al., Blood. 2010;[ASH 2010 Abstract 2180]
Addic&on of AZA to standard induc&on therapy in older pa&ents with AML
![Page 62: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/62.jpg)
Pollyea , et al. abstract 3288 ASH 2010
![Page 63: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/63.jpg)
Novel Agents which may have role in trea&ng elderly AML
• Hedgehog inhibitors.
• PARP inhibitors.
• Aminopep=dase inhibitors: Tosedostat
• Rigoser=b: ON 01910
• HDM2 inhibitors
![Page 64: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/64.jpg)
ü In 2012, the ELN guidelines published in 2010 by an international expert panel remain valid.
ü Addition of GO might become a new standard, at least in some patient subsets.
ü Most recent and current investigations concern: • conventional drug dose intensification • new agent incorporation • allograft stratification on patient-, AML- and stem cell
source-related factors.
CONCLUSIONS
![Page 65: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/65.jpg)
It is exciting to think that the goal of personalized medicine is quickly approaching, but it will require careful thought to implement genomic-based clinical evaluation in a way that is meaninful for patients.
Lucy A. Godley. Profiles in Leukemia. NEJM 2012:366;1152
![Page 66: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/66.jpg)
![Page 67: LEUCEMIA MIELOIDE ACUTA - · PDF fileA.M. Carella U.O.C. Ematologia IRCCS AOU San Martino – IST, Genova LEUCEMIA MIELOIDE ACUTA](https://reader036.vdocument.in/reader036/viewer/2022081507/5a79d2c07f8b9a9b4d8d6b7e/html5/thumbnails/67.jpg)
§ Rilevanza prognostica del profilo genetico integrato.
§ Associazione di target therapy e chemioterapia nei pazienti FLT3 mutati.
§ Trapianto autologo: nuovi protocolli ad alte dosi.